The head of the World Health Organization says the agency is “extremely concerned” by a surge of coronavirus cases, particularity in Europe and North America.
Tedros Adhanom Ghebreyesus told reporters Monday at a regular briefing in Geneva that the case increases are pushing health workers to the “breaking point.”
Tedros returned to WHO headquarters Monday for the first time since self-quarantining for two weeks as a precaution after coming into contact with a person who tested positive for COVID-19.
Tedros also hailed “encouraging news” about COVID-19 vaccines but warned that people should not be complacent, following Monday’s announcement by U.S.-based Moderna. The pharmaceutical company said its experimental vaccine is 94.5% effective against the infection, based on preliminary results from its third and final stage clinical trial.
The WHO’s chief scientist, Soumya Swaminathan, said Monday that she expected there to be "very limited" COVID-19 vaccine doses available in the first half of 2021 for the agency’s global distribution plans.
In its Phase 3 study, Moderna tested its vaccine candidate using 30,000 volunteers. Some of the volunteers were injected with a placebo, while others received the vaccine.
Moderna says in the first analysis, 90 of 95 volunteers who received a placebo came down with COVID-19, the disease caused by the coronavirus. Separately, 11 of those volunteers came down with “serious” cases of the disease and all were in the placebo group.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, chief executive officer of Moderna, in a news release.
“This milestone is only possible because of the hard work and sacrifices of so many. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus.”
The Massachusetts-based pharmaceutical giant developed the vaccine in collaboration with researchers with the U.S. government’s National Institute of Allergy and Infectious Diseases.
Dr. Peter Hotez, a pediatrician and dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, who was not involved in developing any of the COVID-19 vaccines, told that he was encouraged by Moderna’s results, but wanted to see them published in a peer-reviewed journal.
Moderna is now the second potential COVID-19 vaccine to achieve a successful effectiveness rate of more than 90%, coming just a week after U.S.-based Pfizer and German-based BioNTech became the first to announce a critical breakthrough. COVID-19 is the disease caused by the coronavirus.
President Donald Trump reacted to the news about Moderna on Twitter.
“Another Vaccine just announced. This time by Moderna, 95% effective. For those great “historians”, please remember that these great discoveries, which will end the China Plague, all took place on my watch!,” he said.
Projected election winner Joe Biden also responded.
“Today's news of a second vaccine is further reason to feel hopeful. What was true with the first vaccine remains true with the second: we are still months away. Until then, Americans need to continue to practice social-distancing and mask-wearing to get the virus under control,” he said on Twitter.
Moderna’s news also comes on the same day that a unit of U.S. pharmaceutical giant Johnson & Johnson was beginning a third and final stage clinical trial of a potential vaccine in Britain. Janssen Pharmaceuticals will enlist 6,000 volunteers to receive the two-dose experimental vaccine, eventually expanding to 30,000 participants across several nations, including Belgium, Colombia, France, Germany, Spain and the United States.
Another experimental coronavirus vaccine developed by Johnson & Johnson is currently in widespread Phase 3 global trials in Argentina, Brazil, Mexico, South Africa and the United States. The company briefly paused testing of the one-dose vaccine last month after a participant was diagnosed with an unexplained illness.
Meanwhile, younger people who recovered from COVID-19 but continued to experience symptoms suffered lingering damage to multiple organs, according to a new study from Britain.
Observations of more than 200 patients reveal that nearly 70% have damage in one or more organs as long as four months after their initial infection, including the heart and lungs.